API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.accesswire.com/839567/salix-pharmaceuticals-announces-a-phase-2-investigator-initiated-study-of-relistor-methylnaltrexone-bromide-mntx-in-patients-with-resectable-head-and-neck-squamous-cell-carcinoma
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216836
https://www.noramco.com/2022/11/01/noramco-announces-submission-and-reactivation-of-the-drug-master-file-for-active-pharmaceutical-ingredient-methylnaltrexone-bromide/
https://www.accesswire.com/721607/Salix-Will-Present-XIFAXANR-Rifaximin-TRULANCER-Plecanatide-and-RELISTORR-Methylnaltrexone-Bromide-Data-at-The-American-College-of-GastroenterologyR-2022-Annual-Scientific-Meeting
https://www.prnewswire.com/news-releases/new-data-on-cost-impact-of-treating-opioid-induced-constipation-oic-with-fda-approved-medications-including-salixs-relistor-subcutaneous-injection-methylnaltrexone-bromide-in-the-emergency-department-is-published-in-advanc-301509600.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125390
https://www.prnewswire.com/news-releases/salix-will-share-relistor-methylnaltrexone-bromide-data-at-painweek-2021-301368004.html
https://finance.yahoo.com/finance/news/salix-share-relistor-methylnaltrexone-bromide-120200703.html
https://www.prnewswire.com/news-releases/salix-to-highlight-new-data-across-its-portfolio-of-products-at-digestive-disease-week-2020-virtual-meeting-301049876.html
https://www.thepharmaletter.com/in-brief/brief-court-upholds-validity-of-patent-protecting-relistor-tablets
https://www.prnewswire.com/news-releases/salix-announces-two-methylnaltrexone-poster-presentations-for-opioid-induced-constipation-at-the-annual-assembly-of-the-american-academy-of-hospice-and-palliative-medicine-and-hospice-and-palliative-nurses-association-300811677.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125390
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004218/WC500253136.pdf
https://www.businesswire.com/news/home/20180731005522/en/Aegerion%E2%80%99s-Myalepta%C2%AE%E2%96%BC-Approved-Europe-Treatment-Patients-Ultra-Rare
https://www.prnewswire.com/news-releases/summary-judgment-granted-upholding-the-validity-of-formulation-patent-protecting-relistor-injection-300641653.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208594
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208592
http://www.fiercepharma.com/pharma/valeant-touts-salix-salesforce-scale-up-amid-rumors-mass-rep-exit
http://www.fiercebiotech.com/biotech/purdue-inks-shionogi-collab-constipation-med-as-it-awaits-fda-approval
http://www.fiercepharma.com/marketing/how-much-can-a-new-evp-help-valeant-s-badly-battered-derm-unit
http://www.fiercepharma.com/marketing/valeant-looks-to-revive-xifaxan-primary-care-sales-effort-will-it-work
https://www.bloomberg.com/news/articles/2016-11-30/valeant-said-to-plan-to-keep-salix-after-takeda-deal-falls-apart
http://www.prnewswire.com/news-releases/valeant-announces-the-initiation-of-a-primary-care-sales-force-for-xifaxan-and-relistor-300369978.html
http://www.prnewswire.com/news-releases/valeant-and-progenics-announce-the-us-commercial-launch-of-fda-approved-relistor-tablets-300323190.html
http://www.wsj.com/articles/valeant-gets-fda-ok-for-anticonstipation-tablets-developed-by-progenics-1468974726
https://www.pharmacompass.com/pdf/news/fda-appoved-nda-for-salix-pharms-relistor-to-treat-opoid-induced-constipation-1469261946.pdf
http://nordiclifescience.org/sobi-gains-commercial-rights-pharma-swiss/
http://www.prnewswire.com/news-releases/valeant-and-progenics-announce-fda-acceptance-of-nda-submission-for-oral-relistor-300138864.html
http://www.pharmatimes.com/Article/15-06-24/Valeant_Progenics_file_Relistor_pill_in_the_US.aspx
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/04/news_detail_002310.jsp&mid=WC0b01ac058004d5c1